Credit Suisse Ag Ngm Biopharmaceuticals Inc Transaction History

Credit Suisse Ag

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 11, 2023	BUY	$2.44 - $4.53 $29,577 - $54,912	12,122 Added 32.25%	49,704 $128,000
Q1 2023 May 10, 2023	BUY	$3.72 - $5.4 $11,115 - $16,135	2,988 Added 8.64%	37,582 $153,000
Q4 2022 Feb 13, 2023	BUY	$3.41 - $12.93 $23,477 - $89,023	6,885 Added 24.85%	34,594 $173,000
Q3 2022 Nov 10, 2022	BUY	$12.59 - $17.67 $2,442 - $3,427	194 Added 0.71%	27,709 $362,000
Q2 2022 Aug 12, 2022	BUY	$10.58 - $17.5 $31,327 - $51,817	2,961 Added 12.06%	27,515 $352,000
Q1 2022 May 16, 2022	SELL	$13.81 - $18.6 $5,524 - $7,440	-400 Reduced 1.6%	24,554 $374,000
Q4 2021 Feb 14, 2022	BUY	$17.26 - $22.02 $100,884 - $128,706	5,845 Added 30.59%	24,954 $443,000
Q3 2021 Nov 12, 2021	BUY	$20.15 - $26.19 $86,564 - $112,512	4,296 Added 29.0%	19,109 $402,000
Q2 2021 Aug 16, 2021	BUY	$15.06 - $30.03 $223,083 - $444,834	14,813 New	14,813 $292,000

2.6M

300

Ticker NGM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 80,365,904
Description
NGM Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer. The company's product candidates include Aldafermin, an engineered analog of human hormone fibroblast growth factor 19, which is in Phase IIb clinical trial...

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

Stay updated on Credit Suisse Ag with notifications on news.